Aspect Biosystems CEO Tamer Mohamed (L) and Novo Nordisk head of cell therapy Jacob Sten Petersen
Novo Nordisk taps into Canadian biotech’s cell therapies for diabetes and obesity in deal worth up to $2.6B
As Vertex moves its diabetes cell therapies through early-stage clinical testing, longtime diabetes player Novo Nordisk is now looking to do the same via …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
